| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JHEP.2006.09.019 |
| P698 | PubMed publication ID | 17126448 |
| P50 | author | Tetsuya Hosaka | Q56223851 |
| Norio Akuta | Q87747459 | ||
| Yusuke Kawamura | Q90407021 | ||
| Hitomi Sezaki | Q92198438 | ||
| Kenji Ikeda | Q114433562 | ||
| Hiromitsu Kumada | Q114433568 | ||
| Fumitaka Suzuki | Q114923480 | ||
| Masahiro Kobayashi | Q114923755 | ||
| Yoshiyuki Suzuki | Q114923935 | ||
| Yasuji Arase | Q114924322 | ||
| Mariko Kobayashi | Q114924823 | ||
| P2093 | author name string | Hiromi Yatsuji | |
| P433 | issue | 3 | |
| P921 | main subject | ribavirin | Q421862 |
| Hepatitis C virus | Q708693 | ||
| lipoprotein | Q28350 | ||
| hepatitis C | Q154869 | ||
| patient | Q181600 | ||
| P304 | page(s) | 403-410 | |
| P577 | publication date | 2006-11-07 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels | |
| P478 | volume | 46 |
| Q38848401 | A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. |
| Q42574425 | A low serum γ-glutamyltransferase level predicts a sustained virological response in patients with chronic hepatitis C genotype 1. |
| Q36609569 | A lower serum gamma-glutamyltransferase level does not predict a sustained virological response in patients with chronic hepatitis C genotype 1. |
| Q50549709 | A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. |
| Q34226904 | A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus |
| Q43039969 | Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report. |
| Q42263036 | Adjuvant epoetin-β with peginterferon-α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2. |
| Q43034369 | Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment |
| Q50555852 | Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. |
| Q42998703 | Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. |
| Q43033715 | Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin |
| Q43036185 | Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. |
| Q42983421 | Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. |
| Q43039569 | Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. |
| Q42994827 | Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. |
| Q42661947 | An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin |
| Q35077047 | Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91 |
| Q43038409 | Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene |
| Q43036643 | Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients |
| Q42995634 | Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load |
| Q43047740 | Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy |
| Q36050504 | Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients |
| Q42978588 | Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. |
| Q34124888 | Associations between serum lipids and hepatitis C antiviral treatment efficacy |
| Q42986231 | Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study |
| Q42252352 | Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study |
| Q45357130 | Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment |
| Q45362210 | Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients |
| Q37891171 | Cholesterol and chronic hepatitis C virus infection. |
| Q43036190 | Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. |
| Q42982320 | Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis |
| Q43047082 | Controversies in surveillance and early diagnosis of hepatocellular carcinoma. |
| Q42980375 | Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. |
| Q50524187 | Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. |
| Q43047749 | Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy |
| Q43040833 | Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients |
| Q37084557 | Dysmetabolic changes associated with HCV: a distinct syndrome? |
| Q28478142 | Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C |
| Q36184075 | Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy |
| Q42986058 | Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices |
| Q42244766 | Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients |
| Q39556422 | Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis |
| Q42984851 | Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis |
| Q43046546 | Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. |
| Q43041036 | Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment |
| Q43047178 | Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled t |
| Q33948292 | Epidemiology and natural history of hepatitis C virus infection |
| Q52355121 | Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. |
| Q41473188 | Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. |
| Q42220429 | Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. |
| Q50550265 | Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. |
| Q45354663 | Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection. |
| Q43033327 | Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. |
| Q34769764 | Fluvastatin inhibits hepatitis C replication in humans |
| Q28477175 | Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing |
| Q33574642 | Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy |
| Q29619541 | Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C |
| Q38038693 | Genomic variation-guided management in chronic hepatitis C. |
| Q43040102 | Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. |
| Q45353010 | Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology |
| Q42978412 | HCV replication and statin pleotropism: an adjuvant treatment panacea? |
| Q55452571 | Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy. |
| Q42259303 | Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy. |
| Q37015738 | Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease |
| Q37984653 | Hepatocellular carcinoma: towards personalized medicine. |
| Q42984258 | High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus |
| Q34049322 | IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy |
| Q35838595 | IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C |
| Q36541206 | IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients |
| Q34164822 | IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. |
| Q33712188 | Identification of Treatment Efficacy-Related Host Factors in Chronic Hepatitis C by ProteinChip Serum Analysis |
| Q36953735 | Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients |
| Q43001302 | Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes |
| Q43036773 | Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. |
| Q37322478 | Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C |
| Q38224436 | Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview |
| Q45358158 | Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication |
| Q50530986 | Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads. |
| Q43037177 | Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus |
| Q45350857 | Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load. |
| Q37654502 | Individualization of chronic hepatitis C treatment according to the host characteristics |
| Q39267671 | Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. |
| Q34065725 | Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. |
| Q42978534 | Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation |
| Q27488209 | Internal Initiation Stimulates Production of p8 Minicore, a Member of a Newly Discovered Family of Hepatitis C Virus Core Protein Isoforms |
| Q35893868 | Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice |
| Q43038424 | Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. |
| Q36383353 | Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy |
| Q38056643 | Lipids and HCV. |
| Q42981430 | Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma |
| Q42996032 | Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy |
| Q36414090 | NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients |
| Q52699061 | Newly discovered hepatitis C virus minicores circulate in human blood. |
| Q34896257 | Occurrence of genetic modifications in core, 5'UTR and NS5b of HCV associated with viral response to treatment |
| Q37304715 | Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C |
| Q41435455 | Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection |
| Q47550180 | Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma |
| Q43034121 | Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy |
| Q42987712 | Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma |
| Q33959591 | Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C |
| Q43036174 | Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. |
| Q42978648 | Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load |
| Q42247557 | Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. |
| Q42988539 | Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study |
| Q39801024 | Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors |
| Q33689607 | Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis |
| Q42982312 | Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors |
| Q42998840 | Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus |
| Q42987442 | Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction |
| Q40771120 | Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. |
| Q45377963 | Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy |
| Q53123123 | Recent topics on α-fetoprotein. |
| Q37636210 | Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study |
| Q42269917 | Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. |
| Q38121422 | Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. |
| Q36645372 | Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection |
| Q42997927 | Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. |
| Q34154593 | Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy |
| Q43034814 | Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy |
| Q33803007 | Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis |
| Q43046716 | Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection |
| Q42278798 | Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. |
| Q42997897 | Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy |
| Q42929942 | Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin |
| Q42275118 | Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection |
| Q38069609 | Sex hormones and HCV: an unresolved mystery. |
| Q50557398 | Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads. |
| Q50554691 | Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin. |
| Q45365640 | Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance |
| Q37966703 | Tailor-made therapy for viral hepatitis: recent advances |
| Q37006233 | The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients. |
| Q42211503 | The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. |
| Q56441563 | The long way toward understanding host and viral determinants of therapeutic success in HCV infection |
| Q42245708 | Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. |
| Q36973392 | Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines |
| Q37597927 | Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. |
| Q41240010 | Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C. |
| Q50553476 | [Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1]. |
Search more.